About us

Founded in 2015 by two scientists, Géraldine Le Duc (CEO of NH TherAguix) and Pr Olivier Tillement (Professor of Chemistry at University of Lyon), NH TherAguix is a French biotechnology company based in Grenoble. NH TherAguix has developed an innovative theranostic nanodrug called AGuIX® that allows to fight more efficiently against all forms of cancer.
Thanks to a €13M fund raising in 2019 (BPI, Innobio, Omnes, Arbevel, Supernova), NH THerAguix was able to launch a promising portfolio of clinical trials.

Management

Board of directors

Partners

Management

Géraldine Le Duc, PhD

Chief Executive Officer & Co-Founder

30 years of expertise in drugs for radiotherapy and imaging of cancer (Guerbet, INSERM, BNL-USA, ESRF)
More than 100 scientific publications, 4 patents
Discovery of the radiosensitization effect of AGuIX®
PhD in Biomedical Physics

Markus Loeffler, MD & MBA

Chief Medical Officer

More than 20 years of international leadership experience in oncology (Boehringer Ingelheim, Roche, AAA, Mundipharma EDO)
Expertise in all stages of research and clinical development from first in human to market
MD & MBA from INSEAD

Michel Julien, PhD

CMC Director

Over 20 years of experience in parenteral drug research and development
Strong expertise in CMC activities from lead candidate selection to manufacturing process validation including management of CMOs
PhD in Biochemistry

Caroline Cayre

Head of Finance and Administration

25+ years spent in Finance & Business administration, including 15 years in international business environment
Broad industry experience: Audit (PwC), Large international groups (HP), Fast growing SMEs/Start-ups (Aledia)
French Business School (1995) – Studies abroad (Bath-UK), Certified Coach (Teams & Organizations)